Human papillomavirus isolated from transplant-associated porokeratoses of mibelli responsive to topical 5% imiquimod cream

Dermatologic Surgery

Volumn 32, Issue 6, 2006, Pages 858-861

  Esser, Adam C ^a   Pittelkow, Mark R ^b   Randle, Henry W ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD;

ADULT; AGED; ARTICLE; CASE REPORT; CRYOSURGERY; DRUG EFFECT; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; POROKERATOSIS MIBELLI; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VIRUS ISOLATION; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OINTMENTS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POROKERATOSIS;

EID: 33744932440     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32176.x     Document Type: Article

References (25)

1. Silver SG Crawford RI. Fatal squamous cell carcinoma arising from transplant associated porokeratosis. J Am Acad Dermatol 2003 49 : 931 3.
2. Sasson M Krain AD. Porokeratosis and cutaneous malignancy. A review. Dermatol Surg 1996 22 : 339 42.
3. Agarwal S Beth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2002 146 : 338 9.
4. Harrison S Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream. Australas J Dermatol 2003 44 : 281 3.
5. James CD Carlbom E Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988 48 : 5546 51.
6. Berkhout RJ Tieben LM Smits HL, et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995 33 : 690 5.
7. Rust A McGovern RM Gostout BS, et al. Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. J Am Acad Dermatol 2001 44 : 681 6.
8. Herranz P Pizarro A DeLucas R, et al. High incidence of porokeratosis in renal transplant patients. Br J Dermatol 1997 136 : 176 9.
9. Rio B Magana C LeTourneau A, et al. Disseminated superficial porokeratosis after autologous bone marrow transplantation. Bone Marrow Transplant 1997 19 : 77 79.
10. Fields LL White CR Maziarz RT. Rapid development of disseminated superficial porokeratosis after transplant induction therapy. Bone Marrow Transplant 1995 15 : 993 5.
11. Kono T Kobayashi H Ishii M, et al. Synchronous development of disseminated superficial porokeratosis and hepatitis C virus related hepatocellular carcinoma. J Am Acad Dermatol 2000 43 : 966 8.
12. Mizukawa Y Shiohara T. Porokeratosis in patients with hepatitis C virus infection: does hepatitis C virus infection provide a link between porokeratosis and immunosuppression? Br J Dermatol 1999 141 : 163 4.
13. Rodriguez EA Jakubowicz S Chinchilla DA, et al. Porokeratosis of Mibelli and HIV infection. Int J Dermatol 1996 35 : 402.
14. Neumann RA Knobler RM Jurecka W Gebhart W. Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions. J Am Acad Dermatol 1989 21 : 1182 8.
15. Mizukawa Y Shiohara T. Onset of porokeratosis of Mibelli in organ transplant recipients: lack of a search for transmissible agents in these patients [Letter]. J Am Acad Dermatol 2001 44 : 143 4.
16. Munoz N Bosch FX de San Jose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 348 : 518 27.
17. Berkhout RJ Bavinck JN Schegget J. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol 2000 38 : 2087 96.
18. Masini C Fuchs PG Gabrielli F, et al. Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals. Arch Dermatol 2003 139 : 890 4.
19. Harwood CA Surentheran T McGregor JM, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000 61 : 289 97.
20. Storey A Thomas M Kalita A, et al. Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998 393 : 229 34.
21. Arranz-Salas I Sanz-Trelles A Ojeda DB. p53 alterations in porokeratosis. J Cutan Pathol 2003 30 : 455 8.
22. Jackson S Harwood C Thomas M, et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000 14 : 3065 73.
23. Hemmi H Kaisho T Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002 3 : 196 200.
24. Beutner KR Tyring SK Trofatter KF. Imiquimod, a patient-applied immune response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998 42 : 789 94.
25. Arany I Tyring SK Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999 43 : 55 63.